TRV GP V, LLC

Est. AUM

$401.0M

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	RAPPORT THERAPEUTICS, INC.	COM	$223.3M	7135233	55.68%	SOLE
2	SEPTERNA, INC.	COM	$149.4M	6215591	37.25%	SOLE
3	MAZE THERAPEUTICS, INC.	COM	$28.4M	950800	7.08%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.